<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616096</url>
  </required_header>
  <id_info>
    <org_study_id>IAAD01</org_study_id>
    <secondary_id>AZ07-111</secondary_id>
    <nct_id>NCT00616096</nct_id>
  </id_info>
  <brief_title>Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels</brief_title>
  <official_title>Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Luebeck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether immunoadsorption is effective in the
      treatment of severe atopic dermatitis associated with excessively high serum IgE levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of clinical improvement of skin condition, pruritus and sleep disturbance.</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evidence of reduction of concomitant topical and/or systemic medication.</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>immunoadsorption</intervention_name>
    <description>First cycle: week 1, day 1-5
Second cycle: week 5, day 1-5</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Atopical dermatitis

          -  Total serum IgE level above 5000 kU/l

          -  IGA score of 3 or above

          -  No sufficient response to topical corticosteroids/calcineurin inhibitors, UV therapy
             (at least 4 weeks of therapy), systemic corticosteroids and cyclosporin A (at least 8
             weeks of therapy) or no possibility of a prolonged use of this therapy due to adverse
             events/contraindications

          -  18 years of age or above

          -  Effective contraception during therapy

          -  Informed consent

        Exclusion Criteria:

          -  Unfavorable conditions for peripheral venous access

          -  Known hypersensitivity or allergy towards materials used in the adsorber columns

          -  Adequate anticoagulation not possible (e.g. multiple allergies towards various
             anticoagulants)

          -  Extreme bleeding tendency during anticoagulation

          -  Hypercoagulability

          -  Severe cardiovascular disease forbidding extracorporeal circulation

          -  Severe systemic infection

          -  Serum IgG level below 250 mg/dl

          -  Severe immunodeficiency (e.g. AIDS)

          -  Treatment with an ACE inhibitor (discontinue drug at least 72 h before treatment)

          -  Pregnancy

          -  Lactation

          -  A condition that, in the opinion of the investigator, would preclude participation in
             the study (e.g. chronic alcoholism or mental dysfunction)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Detlef Zillikens, M. D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Dermatology, University of L端beck, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, University of L端beck</name>
      <address>
        <city>L端beck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <last_update_submitted>January 27, 2010</last_update_submitted>
  <last_update_submitted_qc>January 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Detlef Zillikens, M. D.</name_title>
    <organization>Department of Dermatology, University of L端beck, Germany</organization>
  </responsible_party>
  <keyword>Serum Immunoglobulin E above 5000 kU/l</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

